COVID-19 Vaccine Policy Development in a Sample of 44 Countries- Key Findings from a December 2021 Survey of National Immunization Technical Advisory Groups (NITAGs)

20 Pages Posted: 27 Jul 2022

See all articles by Anna-Lea Kahn

Anna-Lea Kahn

World Health Organization (WHO)

Christoph Steffen

World Health Organization (WHO)

Louise Henaff

World Health Organization (WHO)

Noni MacDonald

Dalhousie University

Christopher Morgan

Burnet Institute

Ruth Faden

Johns Hopkins University - Berman Institute of Bioethics

Olayinka Folake

Public Health Institute

Shalini Desai

World Health Organization (WHO)

Abstract

National Immunization Technical Advisory Committees (NITAGs) are tasked with the responsibility of guiding ministries of health and national immunization programmes in their policy development processes. Many NITAGs rely on evidence reviewed by the World Health Organization’s (WHO) Strategic Group of Experts (SAGE) on immunization and aim to adapt WHO’s recommendations to their respective contexts. This relationship took on exceptional importance since the onset of the COVID-19 Pandemic, during which NITAGs have expressed a notable struggle to craft appropriate policies on population prioritization and vaccine utilization in the face of supply constraints and complex programmatic and delivery logistics.This online survey was conducted to assess the usefulness of the SAGE products for COVID-19 vaccine policies and to examine the persisting needs and challenges facing NITAGs. Results confirmed that SAGE recommendations concerning COVID-19 vaccines are easy to access, understand, and adapt. They have been found to be comprehensive and timely under the data and time constrained circumstances confronting SAGE. The Global NITAG Network (GNN) appears to be the most popular vehicle for addressing questions among high income countries, in contrast to lower income countries who favour WHO country or regional offices. NITAGs place much value on interaction with other NITAGs, which requires facilitation and could benefit from increased opportunities, especially within regions.  It is further noted that NITAGs have had policy concerns during the pandemic not typically considered by SAGE, such as supply chain logistics and vaccine demand.Learning from the COVID-19 experience offers opportunities to strengthen NITAGs and the pandemic recovery effort through the development of more concrete procedures and consideration of more varied types of data, including implementation effectiveness and uptake data. There is also an increasingly important role for country-level WHO personnel to support NITAGs, while ensuring information and evidence needs of countries are adequately reflected in SAGE deliberations.

Keywords: National immunization technical advisory group, NITAG, SAGE, COVID-19, policy recommendations, Evidence-based decision-making

Suggested Citation

Kahn, Anna-Lea and Steffen, Christoph and Henaff, Louise and MacDonald, Noni and Morgan, Christopher and Faden, Ruth and Folake, Olayinka and Desai, Shalini, COVID-19 Vaccine Policy Development in a Sample of 44 Countries- Key Findings from a December 2021 Survey of National Immunization Technical Advisory Groups (NITAGs). Available at SSRN: https://ssrn.com/abstract=4173965 or http://dx.doi.org/10.2139/ssrn.4173965

Anna-Lea Kahn (Contact Author)

World Health Organization (WHO) ( email )

Christoph Steffen

World Health Organization (WHO) ( email )

Louise Henaff

World Health Organization (WHO) ( email )

20 Avenue Appia
Geneva 27, CH-1211
Switzerland

Noni MacDonald

Dalhousie University ( email )

Division Pediatric Infections Diseases
5850/5980 University Ave PO Box 9700
Halifax, Nova Scotia B3K 6R8
Canada

Christopher Morgan

Burnet Institute ( email )

85 Commercial Road
Melbourne, VIC, 3004
Australia

Ruth Faden

Johns Hopkins University - Berman Institute of Bioethics ( email )

Olayinka Folake

Public Health Institute ( email )

555 12th Street, 10th Floor
Oakland, CA 94607
United States

Shalini Desai

World Health Organization (WHO) ( email )

20 Avenue Appia
Geneva 27, CH-1211
Switzerland

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
36
Abstract Views
175
PlumX Metrics